secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001193125-22-057911
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea reports Q4 net income of $117.1M on Roche revenue recognition; pivots COVID-19 pipeline to combo
--------------------------------------------------------------------------------

- Full year 2021 net income $121.2M vs net loss $10.9M in 2020; revenue of $351.4M from Roche license termination.
- Phase 3 MORNINGSKY trial closed; COVID-19 program shifts to Phase 2 combination with a protease inhibitor in 2H 2022.
- Initiated Phase 2 HCV combination trial of bemnifosbuvir and ruzasvir (in-licensed from Merck) in 2H 2022.
- AT-752 Phase 2 dengue program expected to start 1H 2022 with results late 2022; cash $764.4M at Dec 31, 2021.
- Roche collaboration terminated effective Feb 10, 2022; Atea regains full worldwide rights to bemnifosbuvir.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312522057911/0001193125-22-057911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312522057911/d279167d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-057911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer